portrazza
Pharmaranks rates Portrazza 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Portrazza (Necitumumab) is a medication used to treat Non-Small-Cell Lung Carcinoma.
Necitumumab · by Eli Lilly Co
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Necitumumab
- Form
- Injectable
- Strength
- Necitumumab 800MG/50ML
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- non-small-cell lung carcinoma
- Manufacturer
- Eli Lilly Co
- FDA application
- BLA125547
May treat (source: NIH RxClass)
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Portrazza treat?
- Portrazza (Necitumumab) may be used to treat non-small-cell lung carcinoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Portrazza rated?
- pharmaranks gives Portrazza a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Portrazza?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Portrazza. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Portrazza?
- Portrazza is marketed by Eli Lilly Co. You can see Eli Lilly Co's full profile, rating, and other products on pharmaranks.
- Is Portrazza a brand-name or generic drug?
- Portrazza is a brand-name product with the active ingredient Necitumumab.
- Is Portrazza available over the counter?
- No. Portrazza is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Portrazza come in?
- Portrazza is currently marketed as injectable, per the FDA's National Drug Code Directory.
- Is Portrazza FDA-registered?
- Portrazza is on record with the U.S. FDA under application number BLA125547. You can verify this on its official FDA label.
- Has Portrazza been recalled by the FDA?
- Portrazza has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Portrazza safe?
- There's no single safe-or-not verdict. pharmaranks gives Portrazza a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
emrelis
Telisotuzumab Vedotin-Tllv
gilotrif
Afatinib Dimaleate
hernexeos
Zongertinib
lumakras
Sotorasib
mvasi
Bevacizumab-Awwb
opdivo
Nivolumab
Compare Portrazza head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
portrazza
70/100